CCSG Developmental Funds are critical to the continued growth and development of the Winship Cancer Institute (Winship). These funds provide a critical base of funding enabling Winship to advance its strategic plan by investing in the cancer center's highest priorities. Winship's initial type 1 CCSG award Included approximately $800,000 of Development Funds over three years, and these funds have supported Winship's pilot grant program and two developing shared resources, Bioinfonnatics and Transgenic Mouse Facility. Since April 2009, Winship has distributed 24 pilot grants directly linked to CCSG developmental funds. In addition, the Winship has allocated over $1 million in philanthropic funds for matching pilot grants during the same time period. In total, Winship has distributed over $1.4 million in pilot grant funding to its members to accelerate progress within their research programs, in this current application, Winship is requesting $437,818 in developmental funds per year primarily to continue its pilot grant program and to advance Winship's strategic initiatives through faculty recruitment. This would be allocated as $200,000/year for faculty recruitment in defined domains as identified by the Winship Strategic Plan 2010-2015. Another $200,000/year would continue to support the Winship Pilot Grant Program, with a particular focus on awards that Involve: 1. New Investigations in partnership with the Emory Chemical Biology Center;2. New initiatives in comparative effectiveness research In oncology;3. Research projects in conjunction with an NCI-supported cancer cooperative group or network;4. Research partnerships with investigators from another NCI-designated cancer center;or 5. Investigations in partnership with faculty from another research institution in Georgia. The current request for Developmental Funds in combination with the continued commitment of institutional funds will allow the Executive Director and his leadership team to continue the planned development in a number of strategic recruitments and research development. This support will enable Winship to move toward fulfilling its vision of being a transformative leader in the integration of cancer research, education, and care.
The requested Developmental Funds will provide additional support for the continued growth and development by sponsoring faculty recruitment and pilot grants for the members of the Winship Cancer Institute.
|Berg, Carla J; Stratton, Erin; Esiashvili, Natia et al. (2016) Young Adult Cancer Survivors' Experience with Cancer Treatment and Follow-Up Care and Perceptions of Barriers to Engaging in Recommended Care. J Cancer Educ 31:430-42|
|Patel, Kirtesh R; Chowdhary, Mudit; Switchenko, Jeffrey M et al. (2016) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26:387-94|
|Yoshida, Michihiro; He, Peijian; Yun, C Chris (2016) Transgenic Expression of Human Lysophosphatidic Acid Receptor LPA2 in Mouse Intestinal Epithelial Cells Induces Intestinal Dysplasia. PLoS One 11:e0154527|
|Horton, John R; Liu, Xu; Gale, Molly et al. (2016) Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. Cell Chem Biol 23:769-81|
|Bonner, Michael Y; Karlsson, Isabella; Rodolfo, Monica et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7:12857-68|
|Bajpai, R; Matulis, S M; Wei, C et al. (2016) Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene 35:3955-64|
|Xiao, Canhua; Miller, Andrew H; Felger, Jennifer et al. (2016) A prospective study of quality of life in breast cancer patients undergoing radiation therapy. Adv Radiat Oncol 1:10-16|
|Owonikoko, Taofeek K; Zhang, Guojing; Kim, Hyun S et al. (2016) Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. J Transl Med 14:111|
|Oliver, Daniel E; Patel, Kirtesh R; Switchenko, Jeffrey et al. (2016) Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res 26:35-41|
|Liu, Min; Wang, Hongyan; Lee, Solah et al. (2016) DNA repair pathway choice at various conditions immediately post irradiation. Int J Radiat Biol 92:819-822|
Showing the most recent 10 out of 210 publications